# A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

> **NCT05918614** · PHASE1 · COMPLETED · sponsor: **Kadmon, a Sanofi Company** · enrollment: 8 (actual)

## Conditions studied

- Immune System Disorder (Healthy Volunteer)

## Interventions

- **DRUG:** Belumosudil mesylate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05918614
- **Lead sponsor:** Kadmon, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-28
- **Primary completion:** 2014-06-07
- **Final completion:** 2014-06-07
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918614, "A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05918614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*